What's New:
Recent Quotes:
November 22, 2009 3:39:47 PM EST
- PONIARD PHARMACEUTICALS INC (PARD)
- Last: 2.53
- Chg: 0.16
- Time: N/A
- Overview
- |
- Charts
- |
- News
- |
- Profile
- |
- Financials
- |
- Holdings
- |
- Insider
- |
- Analysts
- |
- SEC Filings
- |
- Options
- |
- Message Board
PONIARD PHARMACEUTICALS INC Headlines
Thursday November 19, 2009
Wednesday November 18, 2009
Tuesday November 17, 2009
- Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results --- Data Presented at AACR-NCI-EORTC's "Molecular Targets and Cancer Therapeutics" Interna
12:52:00 EST - Analyst Downgrades for November 17th
08:36:00 EST - Trading Overview for Poniard Pharmaceuticals Inc. Issued by Beacon Equity
06:50:00 EST - BUYINS.NET: Poniard Pharmaceuticals (PARD) Daily Short Sale Trading Volume Through 11-16-09. Over 15 Million Shares Shorted in Past 3 Months.
05:04:00 EST
Monday November 16, 2009
- PARD: Shares Plunge After Phase 3 SPEAR Trial Fails to Meet Primary Endpoint
13:16:00 EST - Poniard Pharma's Pivotal Phase 3 Trial Of Picoplatin In SCLC Fails To Meet Primary Endpoint; Stock Plunges - Update
09:47:00 EST - Poniard Pharma Says Pivotal Phase 3 SPEAR Trial Of Picoplatin In Small Cell Lung Cancer Fails To Meet Primary Endpoint - Quick Facts
07:44:00 EST - *Poniard Pharmaceuticals Says Pivotal Phase 3 SPEAR Trial Of Picoplatin In Small Cell Lung Cancer Fails To Meet Primary Endpoint
07:21:00 EST - Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer Did Not Meet Primary Endpoint ---- Company to Host Conference Call and Webcast Today at 8:00 a.m. ET --
07:00:00 EST
Sunday November 15, 2009
Friday November 13, 2009
- *Nasdaq OMX Group Issues Results Of Semi-annual Re-ranking Of Nasdaq Biotechnology Index
20:07:00 EST - Semi-Annual Changes to the NASDAQ Biotechnology Index
20:02:00 EST
Tuesday November 10, 2009
Monday November 09, 2009
- *Poniard Pharmaceuticals, Inc. 10% Owner Evnin Luke Sold 78,262 Shares at $8.00 on 11/05/2009 - [PARD]
19:23:00 EST - *Poniard Pharmaceuticals, Inc. Director Simon Nicholas J Iii Sold 78,262 Shares at $8.00 on 11/05/2009 - [PARD]
19:22:00 EST - *Poniard Pharmaceuticals, Inc. 10% Owner Mpm Bioventures Iii Llc Sold 78,262 Shares at $8.00 on 11/05/2009 - [PARD]
19:21:00 EST - *Poniard Pharmaceuticals, Inc. 10% Owner Evnin Luke Sold 264,648 Shares at $8.06 on 11/06/2009 - [PARD]
19:06:00 EST - *Poniard Pharmaceuticals, Inc. Director Simon Nicholas J Iii Sold 264,648 Shares at $8.06 on 11/06/2009 - [PARD]
19:05:00 EST - *Poniard Pharmaceuticals, Inc. 10% Owner Mpm Bioventures Iii Llc Sold 264,648 Shares at $8.06 on 11/06/2009 - [PARD]
19:05:00 EST
Friday November 06, 2009
- Poniard Pharma Nearing D-Day - Stock To Watch
08:56:00 EST
Wednesday November 04, 2009
Tuesday November 03, 2009
- Poniard Pharma Q3 Loss Narrows - Quick Facts
18:22:00 EST - *Poniard Pharma Q3 R&D Expenses $5.40 Mln Vs. $9.02 Mln Last Year
16:37:00 EST - *Poniard Pharma Reports Q3 Loss Per Share Of $0.29 Vs. Loss $0.36 Last Year; Matches Consensus
16:36:00 EST - *Poniard Pharma Q3 Net Loss Applicable To Common Shares $10.00 Mln Vs. Loss $12.36 Mln Last Year
16:36:00 EST - Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update --- Conference Call Today at 5:00 p.m. Eastern Time -
16:05:00 EST
Stocks Marketplace
- 10 Day Free Demo & Fully Functional Software
- Free Market Forecasts
- Why Do Some Know What To Trade, When? Get LiveCharts Real-Time Quotes, Charts, News.
- What Tools Can Take You To Pro-Level Trading Success? Discover The Answer With eSignal.
- How Do The Pros Make Successful Trades? eSignal Learning's Free Seminars Can Show You.
- How To Profit Using Pivot Points, Candlesticks, And Other Indicators